Global Market for Prothrombin Complex Concentrate to Witness Considerable Upsurge During 2018 - 2028

Prothrombin complex concentrate is a combination of blood clotting factors used to treat and prevent bleeding in patients having factor IX deficiency. These clotting factors are the proteins that control bleeding by working together in a cascade of chemical reactions. Patients with life-threatening bleeding urgently require the replacement of these coagulation factors. In this case, prothrombin complex concentrate serves as a concentrated source of the required coagulation factors. Commercially, 2 types of prothrombin complex concentrates are available: 3-factor PCC and 4-factor PCC. There are also low doses of coagulation inhibitors present in PCC, such as protein C, protein S, and heparin, depending on the formulation type. As per various scientific studies, the 4-factor prothrombin complex concentrate is responsible for the faster reversal of warfarin-induced bleeding and has fewer side-effects compared to 3-factor PCC.
Request For Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7032

Prothrombin complex concentrate increases thrombin generation potential in case of bleeding by ensuring adequate levels of key coagulation factors. PCCs also do not require any cross-matching and can be rapidly administered and have minimal risk of infection. Prothrombin complex concentrate is recommended in comparison to other treatment options, such as therapeutic plasma, for the fast reversal of vitamin K antagonists.

The compound is extracted from the cryoprecipitate supernatant of large plasma pools using ion-exchange chromatography after the removal of antithrombin & factor XI. Different processing technologies are employed for the production of either 3-factor or 4-factor concentrate. The final concentrate has the ratio of clotting factors several times higher than normal plasma.

Prothrombin complex concentrate Market: Drivers & Restraints

Development of novel technologies for the production and purification of a large amount of concentrates also promote market growth. Several advantages of prothrombin complex concentrate over fresh-frozen plasma support the market growth of prothrombin complex concentrate. In addition to this, increasing patient care, development of advanced healthcare facilities as well as rising number of trauma cases will also support the market growth. Significantly higher costs, lack of approval in various countries and associated risks, such as thromboembolic complications, immediate allergic reactions and heparin-induced thrombocytopenia, are some of the factors limiting the market growth of prothrombin complex concentrate.

Prothrombin complex concentrate Market: Segmentation

Segmentation by Product Type:

3 Factor Prothrombin Complex Concentrate
4 Factor ProthrombinComplex Concentrate
Segmentation by End User

Hospitals
Clinics
Ambulatory Surgical Centers
Prothrombin complex concentrate Market: Overview

Increasing interest is being witnessed in the prothrombin complex concentrate products to be used as therapy for perioperative and trauma-related bleeding. There exists variations in different countries in terms of licensing status and availability of prothrombin complex concentrates. There are very few companies involved in the production of prothrombin complex concentrate. Several studies are still going on to further investigate the use of prothrombin complex concentrate in cases of trauma-related bleeding. There exist opportunities for the market players to develop more effective and economical products.
Request For Report Table of Content (TOC): https://www.futuremarketinsights.com/toc/rep-gb-7032

Prothrombin complex concentrate Market: Region-wise Outlook

Geographically, North America holds the largest market share in the prothrombin complex concentrate owing to higher adoption of the product in treatments and also because the the region supports significant developments in terms of product enhancements, which will also drive the market. North America is followed by the Western Europe market due to the developed healthcare infrastructure, easy accessibility to healthcare facilities and favorable reimbursement scenario. Japan also represents a developed market for prothrombin complex concentrate. The Asia-Pacific market is anticipated to witness significant growth owing to the advancement of healthcare facilities and adoption of latest techniques for treatments. MEA region is expected to witness slow growth rate due to the poor healthcare infrastructure in most parts of the region as well as unavailability of healthcare services to most of the population.

Prothrombin complex concentrate Market Treatment Market: Key Players

Some of the players in the Prothrombin complex concentrate market are CSL Behring, China Biologic Products Holdings, Inc., Octapharma AG, Baxter, Shire US Inc., Novo Nordisk, Grifols, Kedrion S.p.A and others.

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com/

This release was published on openPR.